Breaking Down SG&A Expenses: Novartis AG vs GSK plc

A Comparative Analysis of SG&A Expenses: Novartis AG vs GSK plc

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two giants: Novartis AG and GSK plc, from 2014 to 2023. Over this period, Novartis AG consistently outspent GSK plc, with an average SG&A expense of approximately 15% higher. Notably, in 2018, Novartis AG peaked with expenses reaching 16.47 billion, while GSK plc's highest was in 2020 at 11.46 billion. Interestingly, both companies showed a downward trend in 2023, with Novartis AG's expenses dropping by 24% from its 2018 peak. This trend may indicate strategic shifts towards more efficient operations or increased investment in other areas. As the pharmaceutical landscape continues to change, these financial insights provide a glimpse into the strategic priorities of these industry leaders.